標(biāo)題: Titlebook: Anticoagulation Therapy; Joe F. Lau,Geoffrey D. Barnes,Michael B. Streiff Book 2018 Springer International Publishing AG, part of Springer [打印本頁(yè)] 作者: 烹飪 時(shí)間: 2025-3-21 19:16
書(shū)目名稱Anticoagulation Therapy影響因子(影響力)
作者: Fraudulent 時(shí)間: 2025-3-21 22:12 作者: 創(chuàng)新 時(shí)間: 2025-3-22 03:29
https://doi.org/10.1007/978-3-319-73709-6anticoagulation therapy; pharmacologic properties of anticoagulants; clinical applications of anticoag作者: KEGEL 時(shí)間: 2025-3-22 07:47 作者: 半導(dǎo)體 時(shí)間: 2025-3-22 10:25
https://doi.org/10.1007/978-3-658-44390-0uman anatomy in health and disease led to greater understanding of the pathophysiology of thrombotic disease and the first treatments for it. Modern approaches to treatment of arterial and venous thromboembolism emerged in the late 19th and 20th centuries with the identification of acetylsalicylic a作者: 構(gòu)成 時(shí)間: 2025-3-22 16:25 作者: 山羊 時(shí)間: 2025-3-22 17:08
https://doi.org/10.1007/978-3-540-78618-4dications, including the treatment of venous thromboembolism, thromboprophylaxis, and acute coronary syndromes. In this chapter, we review the evidence-based recommendations and pharmacology of both UFH and LMWH with a detailed description of their mechanisms of action, pharmacokinetics, and pharmac作者: 領(lǐng)導(dǎo)權(quán) 時(shí)間: 2025-3-22 21:31
https://doi.org/10.1007/978-3-540-78618-4es. These include a non-specific mechanism of action, high degree of non-specific binding to plasma components, unpredictable pharmacokinetics and pharmacodynamics, considerable inter- and intra-patient variability, a narrow therapeutic index, need for routine monitoring, and the potential for adver作者: 天然熱噴泉 時(shí)間: 2025-3-23 03:08 作者: Feature 時(shí)間: 2025-3-23 08:51 作者: Clinch 時(shí)間: 2025-3-23 13:09 作者: 等級(jí)的上升 時(shí)間: 2025-3-23 17:38
Grundelemente der Programmierung,fe and effective anticoagulation relies upon an organized system of care delivery, close collaboration between healthcare teams, effective communication with patients, and anticoagulation management performed by healthcare professionals with specialized training. The anticoagulation management servi作者: Exclude 時(shí)間: 2025-3-23 21:25 作者: 牽索 時(shí)間: 2025-3-24 00:54 作者: LAITY 時(shí)間: 2025-3-24 03:36 作者: 租約 時(shí)間: 2025-3-24 10:03
Marco Nirschl,Laurina Steinberg, and left atrial appendage closure devices, carry dual risks of bleeding and thromboembolism. Many patients undergoing these procedures are maintained on anticoagulation with either warfarin or one of several direct oral anticoagulants, e.g., dabigatran, rivaroxaban, apixaban, and edoxaban. There a作者: 我不死扛 時(shí)間: 2025-3-24 11:25
https://doi.org/10.1007/978-3-662-55271-1h approaches ranging from the open or minimally invasive surgical to the percutaneous endovascular. Treatments that involve securing prosthetic material in, or in communication with, the heart are employed in a variety of cardiac pathologies, including valvular heart disease, cardiomyopathy, and und作者: hyperuricemia 時(shí)間: 2025-3-24 15:42 作者: habile 時(shí)間: 2025-3-24 21:00
Einstieg in die Hochschulmathematikcurrent thrombotic events and that this predisposition was inherited in an autosomal dominant fashion. Since his initial observation, our current understanding of the pathogenesis of thromboembolism has evolved significantly. The current model for pathologic thrombus formation emphasizes the interac作者: 造反,叛亂 時(shí)間: 2025-3-25 01:20 作者: meritorious 時(shí)間: 2025-3-25 06:39
https://doi.org/10.1007/978-3-662-62034-2lex. However, delayed diagnosis and inadequate or inappropriate treatment can lead to life- and limb-threatening outcomes. This chapter will describe the syndrome of HIT (and HITT—heparin-induced thrombocytopenia with thrombosis) as it is now known, including its history, pathophysiology, diagnostic作者: 完全 時(shí)間: 2025-3-25 11:09
Introduction,uman anatomy in health and disease led to greater understanding of the pathophysiology of thrombotic disease and the first treatments for it. Modern approaches to treatment of arterial and venous thromboembolism emerged in the late 19th and 20th centuries with the identification of acetylsalicylic a作者: wreathe 時(shí)間: 2025-3-25 13:27
Warfaringh very effective for prevention and treatment of venous and arterial thromboembolism, warfarin has a narrow therapeutic index, many drug, disease, and dietary interactions, and requires frequent monitoring and dose adjustments (Ageno et al., Chest 141(2 Suppl):e44S–88S, 2012; Holbrook et al., Chest作者: 新娘 時(shí)間: 2025-3-25 18:06
Unfractionated Heparin and Low-Molecular-Weight Heparindications, including the treatment of venous thromboembolism, thromboprophylaxis, and acute coronary syndromes. In this chapter, we review the evidence-based recommendations and pharmacology of both UFH and LMWH with a detailed description of their mechanisms of action, pharmacokinetics, and pharmac作者: languid 時(shí)間: 2025-3-25 19:59
Parenteral Anticoagulants: Direct Thrombin Inhibitors and Pentasaccharideses. These include a non-specific mechanism of action, high degree of non-specific binding to plasma components, unpredictable pharmacokinetics and pharmacodynamics, considerable inter- and intra-patient variability, a narrow therapeutic index, need for routine monitoring, and the potential for adver作者: BRIBE 時(shí)間: 2025-3-26 03:38
Direct Oral Anticoagulantsan—have been approved for prevention of stroke in non-valvular atrial fibrillation and treatment of venous thromboembolism (VTE). All except edoxaban also are approved to prevent VTE in hip and knee replacement surgery. In the atrial fibrillation trials, the DOACs were non-inferior to warfarin dose-作者: 字形刻痕 時(shí)間: 2025-3-26 06:35
Anticoagulation Reversal such therapy have to be outweighed against the risks of major bleeding complications. Such risk varies according to age and has been reported to be as low as 2–3% per year in adults to as high as 6–8% per year in the elderly. Reversal strategies are important both for the treatment of such major he作者: 作繭自縛 時(shí)間: 2025-3-26 11:49
Transitioning Between Anticoagulantsrsible, does not require monitoring, and can be used in patients with end-stage renal disease and moderate-severe liver dysfunction—is not available to date. Currently, the differences in the pharmacokinetic and pharmacodynamic properties of each agent allow for a unique, individualized anticoagulat作者: Emasculate 時(shí)間: 2025-3-26 13:46
The Anticoagulation Clinicfe and effective anticoagulation relies upon an organized system of care delivery, close collaboration between healthcare teams, effective communication with patients, and anticoagulation management performed by healthcare professionals with specialized training. The anticoagulation management servi作者: 慷慨不好 時(shí)間: 2025-3-26 19:35
Perioperative Management of Anticoagulantstients scheduled for surgery is challenging, as the interruption of therapy may increase the risk of thromboembolism, and continuation may predispose patients to increased peri- and intraoperative bleeding risks. It is therefore crucial to conduct an individualized and thorough periprocedural assess作者: Custodian 時(shí)間: 2025-3-27 00:29 作者: Interdict 時(shí)間: 2025-3-27 02:09
Antithrombotic Therapy for Patients with Atrial FibrillationAnticoagulation decreases stroke risk in patients with AF, but benefit comes at the risk of bleeding, including intracerebral hemorrhage (ICH). The vitamin K antagonist (VKA), warfarin (target INR 2.0–3.0), is more effective than antiplatelet or no therapy for thromboembolism prevention, but a narro作者: Delirium 時(shí)間: 2025-3-27 06:12 作者: Ruptured-Disk 時(shí)間: 2025-3-27 10:38 作者: BRAWL 時(shí)間: 2025-3-27 14:53 作者: engender 時(shí)間: 2025-3-27 20:20
Thrombophilic Statescurrent thrombotic events and that this predisposition was inherited in an autosomal dominant fashion. Since his initial observation, our current understanding of the pathogenesis of thromboembolism has evolved significantly. The current model for pathologic thrombus formation emphasizes the interac作者: Climate 時(shí)間: 2025-3-27 22:59
Thrombophilia Testinge best possible diagnosis and understanding of their medical condition. However, laboratory testing for thrombophilia is overused, frequently misunderstood, and in many cases ordered without a good understanding of the results. Laboratory testing for thrombophilia may be affected by many patient-rel作者: 虛構(gòu)的東西 時(shí)間: 2025-3-28 05:21
Heparin-Induced Thrombocytopenialex. However, delayed diagnosis and inadequate or inappropriate treatment can lead to life- and limb-threatening outcomes. This chapter will describe the syndrome of HIT (and HITT—heparin-induced thrombocytopenia with thrombosis) as it is now known, including its history, pathophysiology, diagnostic作者: HALL 時(shí)間: 2025-3-28 08:18 作者: Granular 時(shí)間: 2025-3-28 10:39
https://doi.org/10.1007/978-3-540-78618-4ernative anticoagulants: pentasaccharides and parenteral direct thrombin inhibitors. Optimized safety and efficacy of these drugs require familiarity with their pharmacology, clinical utility, and practical management.作者: exceed 時(shí)間: 2025-3-28 15:49 作者: SKIFF 時(shí)間: 2025-3-28 19:39 作者: synovial-joint 時(shí)間: 2025-3-29 01:30
ologic properties of various anticoagulants.Details the clinThis book presents the latest evidence and guidelines supporting the use of anticoagulant therapy for various clinical scenarios. The field of anticoagulation therapy is evolving rapidly, particularly since the arrival and widespread adopti作者: 向外才掩飾 時(shí)間: 2025-3-29 05:11 作者: Kinetic 時(shí)間: 2025-3-29 08:41
Heparin-Induced Thrombocytopeniathe syndrome of HIT (and HITT—heparin-induced thrombocytopenia with thrombosis) as it is now known, including its history, pathophysiology, diagnostic process with the current testing paradigm, and updated treatment options for HIT.作者: endure 時(shí)間: 2025-3-29 14:24 作者: BAN 時(shí)間: 2025-3-29 17:36
https://doi.org/10.1007/978-3-540-78618-4ns for each agent in addition to considerations that should be evaluated when treating certain patient populations. Finally, we discuss various reversal strategies and complications that can arise from their use.作者: 方便 時(shí)間: 2025-3-29 21:16 作者: Custodian 時(shí)間: 2025-3-29 23:54 作者: 主講人 時(shí)間: 2025-3-30 06:41 作者: 施魔法 時(shí)間: 2025-3-30 08:51 作者: Detoxification 時(shí)間: 2025-3-30 13:17
Einstieg in Lean Administrationment for risk of thromboembolism and bleeding. This chapter will outline the management of warfarin, direct oral anticoagulants, and antiplatelet agents in the perioperative setting. Topics such as short-term parenteral or “bridging” therapy, bleeding risk stratification, and thromboembolic risk stratification will be addressed.作者: 航海太平洋 時(shí)間: 2025-3-30 20:23
tegrated throughout the book. Featuring contributions from authorities in the field, .Anticoagulation Therapy. is an essential resource for cardiologists, vascular medicine specialists, hematologists, internist978-3-030-08840-8978-3-319-73709-6作者: 揉雜 時(shí)間: 2025-3-30 22:18
Book 2018ted. Clinical vignettes, algorithms, clinical pearls, and self-assessment questions are integrated throughout the book. Featuring contributions from authorities in the field, .Anticoagulation Therapy. is an essential resource for cardiologists, vascular medicine specialists, hematologists, internist作者: intention 時(shí)間: 2025-3-31 01:52 作者: Chronic 時(shí)間: 2025-3-31 08:23
https://doi.org/10.1007/978-3-540-78618-4an with serious bleeding or in need of an urgent invasive procedure. A reversal agent for the factor Xa inhibitors has been studied but is not yet approved. To date, data on use of the DOACs in patients with cancer or thrombophilia or at extremes of weight are sparse, as few of these patients were i作者: 顯示 時(shí)間: 2025-3-31 10:31
Grundelemente der Programmierung,nant or exclusive inhibition of one coagulation protein. As a result, the most common reversal strategies for the treatment and prevention of bleeding caused by older anticoagulants are based on the use of drugs and/or blood products that replace and/or boost the synthesis of coagulation proteins in作者: 不透明 時(shí)間: 2025-3-31 13:55
Grundelemente der Programmierung,gely extrapolated from pharmacokinetic data, as well as from expert opinions. Despite limited data, better understanding on how to safely implement a transition from one anticoagulant drug to another is of utmost importance to minimize the risk of recurrent thromboembolic events and hemorrhagic comp作者: legislate 時(shí)間: 2025-3-31 19:11
Grundelemente der Programmierung,therapy, manage anticoagulant dosing, provide systematic and ongoing patient monitoring, provide up-front and ongoing patient education, and coordinate with other providers involved in the care of anticoagulated patients. The availability of DOACs has added another critical AMS function which is to 作者: 雀斑 時(shí)間: 2025-3-31 22:20 作者: medium 時(shí)間: 2025-4-1 02:17
Marco Nirschl,Laurina Steinberg to relatively rapid uptake in practice. We review these data along with subgroup analyses, post-marketing studies, practice-based evidence, and consensus guidance applicable to patients with advanced age, prior stroke, impaired renal function, diabetes, heart failure, coronary disease, or undergoin作者: Synovial-Fluid 時(shí)間: 2025-4-1 09:48
Marco Nirschl,Laurina Steinbergished transesophageal echocardiogram (TEE) and short-term anticoagulation as an alternative to therapeutic anticoagulation with dose-adjusted warfarin for 3?weeks prior to and 4?weeks post-cardioversion. Left-sided ablation procedures are typically done with heparin boluses and infusion with target 作者: 漂亮 時(shí)間: 2025-4-1 12:49 作者: HERE 時(shí)間: 2025-4-1 15:46
Einstieg in die Hochschulmathematik. Thrombophilia refers to congenital or acquired predispositions to thrombus formation. Here, we review the currently established hereditary and acquired thrombophilias. We will review genetic thrombophilic conditions such as factor V Leiden, the prothrombin gene 20210 mutation, protein C and S defi作者: goodwill 時(shí)間: 2025-4-1 19:54 作者: 豐滿有漂亮 時(shí)間: 2025-4-2 00:19 作者: aneurysm 時(shí)間: 2025-4-2 05:30
